HomeNewsBusinessMarketsBreezing through COVID-19 storm! This retail stock owned by Radhakishan Damani can be a multibagger

Breezing through COVID-19 storm! This retail stock owned by Radhakishan Damani can be a multibagger

At a time when most of the midcaps are reeling under pressure, DMart stands out with an outperformance of more than 20 percent, so far, in 2020.

April 09, 2020 / 12:06 IST
Story continues below Advertisement

Veteran stock market investor Radhakishan Damani-led Avenue Supermarts seems to be breezing through the coronavirus storm. The stock, locked in 5 percent upper circuit six times since March, has rallied more than 23 percent in 2020.

Story continues below Advertisement

Avenue Supermarts, which operates the supermarket chain DMart, has been on the analysts' radar for its strong fundamentals.

Some experts place it in the category of a multibagger amid the COVID-19 lockdown being a top retail player. It is also among the top picks for many domestic brokerages.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show